TY - JOUR
T1 - Selected biological issues affecting relapse after stem cell transplantation
T2 - role of T-cell impairment, NK cells and intrinsic tumor resistance
AU - van den Brink, Marcel
AU - Uhrberg, Markus
AU - Jahn, Lorenz
AU - DiPersio, John F.
AU - Pulsipher, Michael A.
N1 - Funding Information:
Genomics Program, Cycle for Survival and P30 CA008748 MSK Cancer Center Support Grant/Core Grant. The work of MU was supported by the Deutsche Krebshilfe e.V. (project 110351) and the research commission of the Medical faculty of the Heinrich Heine University. The work of LJ was supported by the European Molecular Biology Organization (EMBO; ALTF 431-2017) and the MSK Sawiris Foundation Myeloma and Transplant Research Award. The work of MAP was supported by 2UG1HL069254-17 (NHLBI/NCI), R01 CA181050 (NCI), R34HL133384 (NHLBI) and U01AI126612 (NIAID), and by the Johnny Crisstopher Children’s Charitable Foundation St. Baldrick’s Consortium Grant.
Funding Information:
Acknowledgements The work of MvdB was supported by the National Institutes of Health award numbers R01-HL069929 (MvdB), R01-AI101406 (MvdB), P01-CA023766 (RJ O’Reilly) and Project 4 of P01-CA023766 (MvdB). Support was also received from The Lymphoma Foundation, The Susan and Peter Solomon Divisional
Publisher Copyright:
© 2018, Macmillan Publishers Limited, part of Springer Nature.
PY - 2018/8/1
Y1 - 2018/8/1
N2 - The graft vs. leukemia (GvL) effect as a method of preventing relapse is well described after allogeneic hematopoietic cell transplantation (HCT), but the mechanisms to this effect and how tumor sometimes develops resistance to GvL are just beginning to be understood. This article reviews and expands upon data presented at the Third International Workshop on Biology, Prevention and Treatment of Relapse after Stem Cell Transplantation held in Hamburg, Germany, in November 2016. We first discuss in detail the role that T-cell impairment early after HCT plays in relapse by looking at data from T cell-depleted approaches as well as the clear role that early T-cell recovery has shown in improving outcomes. We then review key findings regarding the role of specific KIR donor/recipient pairings that contribute to relapse prevention after HCT for several tumor types. Finally, we discuss a unique mouse model following the development of tumor resistance to GvL. Detailed molecular characterization of events marking the development of tumor resistance to the immunotherapy of GvL may help in developing future strategies to overcome immune escape.
AB - The graft vs. leukemia (GvL) effect as a method of preventing relapse is well described after allogeneic hematopoietic cell transplantation (HCT), but the mechanisms to this effect and how tumor sometimes develops resistance to GvL are just beginning to be understood. This article reviews and expands upon data presented at the Third International Workshop on Biology, Prevention and Treatment of Relapse after Stem Cell Transplantation held in Hamburg, Germany, in November 2016. We first discuss in detail the role that T-cell impairment early after HCT plays in relapse by looking at data from T cell-depleted approaches as well as the clear role that early T-cell recovery has shown in improving outcomes. We then review key findings regarding the role of specific KIR donor/recipient pairings that contribute to relapse prevention after HCT for several tumor types. Finally, we discuss a unique mouse model following the development of tumor resistance to GvL. Detailed molecular characterization of events marking the development of tumor resistance to the immunotherapy of GvL may help in developing future strategies to overcome immune escape.
UR - http://www.scopus.com/inward/record.url?scp=85040948115&partnerID=8YFLogxK
U2 - 10.1038/s41409-017-0078-0
DO - 10.1038/s41409-017-0078-0
M3 - Review article
C2 - 29367714
AN - SCOPUS:85040948115
SN - 0268-3369
VL - 53
SP - 949
EP - 959
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 8
ER -